leisure time -WSS

leisure time

author：hotspot 2025-09-29 22:47:43 - browse：3648

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Supreme Court to hear if Covid misinformation is protected speech

knowledge

entertainment

WSS

Neuroscience’s long legacy of racism

Physicians and social media: If you see something, say something?

Obesity drug from Roche shows promise in early study

WuXi Biologics beefs up its lobbying operation

SCOTUS questions limit to govt efforts to fight misinformation

Hottest summer in 2,000 years puts focus on extreme heat, health

focus

leisure time

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Free medical tuition alone isn't enough to close gaps in primary care

The high cost of giving birth even with insurance

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

The high cost of giving birth even with insurance

As H5N1 spreads in cows, experts warn against drinking raw milk

Dobbs anniversary: the lost opportunity of abortion as health care

ALS treatment from Biogen, Ionis fails in study

Sports medicine is finally prioritizing gender equality

Physicians and social media: If you see something, say something?

hotspot

Ripples from Flovent's discontinuation is killing children with asthma

Lilly’s weekly insulin works as well as daily products, new studies show

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

As H5N1 spreads in cows, experts warn against drinking raw milk

Plastic surgeons increase patient psychiatric screenings

Hottest summer in 2,000 years puts focus on extreme heat, health

focus

knowledge

entertainment

focus